Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)

Krishnamurthy, A., Wang, H., Rhee, J. C., Davar, D., Moy, R. H., Ratner, L., Christner, S. M., Holleran, J. L., Deppas, J., Sclafani, C., Schmitz, J. C., Gore, S., Chu, E., Bakkenist, C. J., Beumer, J. H., & Villaruz, L. C. (2025). Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-024-04745-6
Authors:
Anuradha Krishnamurthy
Hong Wang
John C Rhee
Diwakar Davar
Ryan H Moy
Lee Ratner
Susan M Christner
Julianne L Holleran
Joshua Deppas
Carina Sclafani
John C Schmitz
Steve Gore
Edward Chu
Christopher J Bakkenist
Jan H Beumer
Liza C Villaruz
Affiliated Authors:
Ryan H Moy
Columbia Affiliation:
Subjects:
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Leucovorin (MeSH)
Fluorouracil (MeSH)
Camptothecin (MeSH)
Gastrointestinal Neoplasms (MeSH)
Ataxia Telangiectasia Mutated Proteins (MeSH)
Author Keywords:
atr inhibition
bay 1895344
elimusertib
folfiri
pharmacokinetics
elink
Publication Type:
Article
Unique ID:
10.1007/s00280-024-04745-6
PMID:
39841295
DOI:
10.1007/s00280-024-04745-6
Journal:
Cancer Chemotherapy and Pharmacology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: